Recent whole genome/exome sequencing studies of Ewing sarcoma tumors12,13,54–56 identified PARP-1/2 mutations in only 1 out of 279 (0.36%) and 2 out of 279 (0.72%) patient tumor samples, respectively. This evidence concerns the gene PARP1 and neoplasm.